NEU 1.03% $19.30 neuren pharmaceuticals limited

ROW Rights, page-2

  1. 669 Posts.
    lightbulb Created with Sketch. 60
    There is no reason for another backended deal when we have been told by the managemrnt that it’s now fully funded and judging by the market reaction, they should know the market hated the backended deal they did. Why would they even bother 
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.